RT Journal Article
SR Electronic
T1 Public Health Interventions for Fractional Optimal Control of Buruli Ulcer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.05.24313151
DO 10.1101/2024.09.05.24313151
A1 Nortey, Solomon
A1 Akorly, Ernest
A1 Dadzie, Mark
A1 Moore, Stephen E.
YR 2024
UL http://medrxiv.org/content/early/2024/09/06/2024.09.05.24313151.abstract
AB Buruli Ulcer, a devastating skin disease caused by Mycobacterium Ulcerans, poses considerable public health challenges in endemic areas. This article focuses on the use of fractional optimal control theory to prevent the spread of Buruli ulcers via integrated public health interventions. We formulated a mathematical model using the Atangana-Baleanu-Caputo fractional order derivative operator. We investigated the model’s existence and uniqueness and presented numerical simulations using the predict-evaluate-correct-evaluate (PECE) method of Adam-Bashforth Moulton. We also study the fractional optimal control problem (FOCP) to minimize the spread of the disease in the endemic regions. We employ the Fractional Pontryagin’s Maximum Principle (FPMP) and implement the forward-backward method to determine the extremals of the problem. Four control strategies were implemented: promoting health education on the use of protective clothing, enhancing vaccination rates, improving treatment protocols for infected individuals, and spraying insecticides to reduce water-bug populations. After examining the optimal control dynamics of the Buruli ulcer transmission model via multiple simulations with and without control, we discover that there is a substantial decrease in the population of infected humans and the water-bug population. Hence we conclude that the best strategy to implement is by applying all the control strategies suggested.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo Data associated in the manuscript